Market Exclusive

STELLAR BIOTECHNOLOGIES, INC. (NASDAQ:SBOT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

STELLAR BIOTECHNOLOGIES, INC. (NASDAQ:SBOT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02.

Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

(e)

On March 23, 2017, Stellar Biotechnologies, Inc. (the Company)
held its 2017 annual general meeting of shareholders (the Annual
Meeting). At the Annual Meeting, the Companys shareholders
approved the Companys 2017 Incentive Compensation Plan. A
description of the material terms and conditions of the 2017
Incentive Compensation Plan appears on pages 35-45 of the
Companys definitive proxy statement for the Annual Meeting filed
with the Securities and Exchange Commission on February 1, 2017
and such description is incorporated herein by reference. This
summary is qualified in its entirety by the full text of the 2017
Incentive Compensation Plan, which is filed herewith as Exhibit
10.1 to this Current Report on Form 8-K and is incorporated
herein by reference.

Item 5.07. Submission of Matters to a Vote of Security
Holders.

Set forth below are the matters submitted to the shareholders at
the Annual Meeting, all of which were approved:

the election of seven (7) directors to serve on the Companys
Board of Directors until the Companys annual general meeting
of shareholders to be held in 2018 or until their successors
are duly elected and qualified;
the ratification of the appointment of Moss Adams LLP as the
Companys auditors and independent registered public
accounting firm for the fiscal year ending September 30,
2017; and
the approval of the Companys 2017 Incentive Compensation
Plan.

The final voting results with respect to each matter are set
forth below.

Election of Directors

NOMINEE FOR VOTES WITHHELD VOTES ABSTAIN BROKER NON-VOTES
Tessie M. Che 1,402,807 216,655 3,300,035
Paul Chun 1,401,459 218,003 3,300,035
David L. Hill 1,564,896 54,566 3,300,035
Daniel E. Morse 1,537,645 81,817 3,300,035
Frank R. Oakes 1,565,743 53,719 3,300,035
Charles V. Olson 1,406,768 212,694 3,300,035
Mayank D. Sampat 1,401,681 217,781 3,300,035

Ratification of the Appointment of Moss Adams LLP as
the Companys Auditors and Independent Registered Public
Accounting Firm for the Fiscal Year Ending September 30,
2017

FOR VOTES WITHHELD VOTES ABSTAIN BROKER NON-VOTES
4,840,165 79,332

Approval of 2017 Incentive Compensation
Plan

FOR VOTES AGAINST VOTES ABSTAIN BROKER NON-VOTES
1,311,522 307,940 3,300,035

Item 8.01. Other Events.

Effective March 23, 2017, the Board approved the following
Chairpersons and members of each of its standing committees:

Nominating and Corporate
Audit Committee Compensation Committee Governance Committee
Mayank D. Sampat, Chair David L. Hill, Chair Paul Chun, Chair
David L. Hill Mayank D. Sampat David L. Hill
Paul Chun Daniel E. Morse Mayank D. Sampat
Paul Chun
Charles V. Olson
Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No. Description
10.1 2017 Incentive Compensation Plan.

About STELLAR BIOTECHNOLOGIES, INC. (NASDAQ:SBOT)
Stellar Biotechnologies, Inc. is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-targeting agent to create immunotherapies for the treatment of a range of diseases. The Company’s core business is developing and commercializing Keyhole Limpet Hemocyanin for use in immunotherapy and immunodiagnostic applications. The Company’s Stellar KLH product offerings include Stellar KLH protein for conjugation and as carrier molecule in immunotherapy development; Stellar KLH protein and enzyme-linked immunosorbent assay (ELISA) test kits for immune function testing, and Custom KLH formulations, adjuvants, conjugations and fill finishes for preclinical research and drug development applications. STELLAR BIOTECHNOLOGIES, INC. (NASDAQ:SBOT) Recent Trading Information
STELLAR BIOTECHNOLOGIES, INC. (NASDAQ:SBOT) closed its last trading session down -0.02 at 1.60 with 36,014 shares trading hands.

Exit mobile version